318 related articles for article (PubMed ID: 21850283)
1. Denosumab: an update.
Bogado CE; Boailchuk JA; Zanchetta MB; Massari FE; Zanchetta JR
Drugs Today (Barc); 2011 Aug; 47(8):605-13. PubMed ID: 21850283
[TBL] [Abstract][Full Text] [Related]
2. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
3. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
4. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
5. [Denosumab for treatment of postmenopausal osteoporosis].
Syversen U; Halse JI; Geisler J; Eriksen EF
Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
[TBL] [Abstract][Full Text] [Related]
6. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoporosis with denosumab.
Lewiecki EM
Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
[TBL] [Abstract][Full Text] [Related]
8. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Moen MD; Keam SJ
Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
[TBL] [Abstract][Full Text] [Related]
9. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
10. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
Lewiecki EM
Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
[TBL] [Abstract][Full Text] [Related]
12. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
13. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for treatment of postmenopausal osteoporosis.
Chitre M; Shechter D; Grauer A
Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
16. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
Sugimoto T
Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
[TBL] [Abstract][Full Text] [Related]
17. Denosumab.
Pageau SC
MAbs; 2009; 1(3):210-5. PubMed ID: 20065634
[TBL] [Abstract][Full Text] [Related]
18. Denosumab: What's new?
Bogado CE; Zanchetta MB; Boailchuk JA; Massari FE; Zanchetta JR
Curr Osteoporos Rep; 2011 Mar; 9(1):12-9. PubMed ID: 21132405
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on denosumab in postmenopausal osteoporosis.
Moen MD; Keam SJ
BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
[TBL] [Abstract][Full Text] [Related]
20. Denosumab in osteoporosis and oncology.
Burkiewicz JS; Scarpace SL; Bruce SP
Ann Pharmacother; 2009 Sep; 43(9):1445-55. PubMed ID: 19622756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
